Menu
Search
|

Menu

Close
X

DURECT Corp DRRX.OQ (NASDAQ Stock Exchange Global Market)

1.09 USD
-0.03 (-2.68%)
As of 2:29 AM IST
chart
Previous Close 1.12
Open 1.12
Volume 103,807
3m Avg Volume 186,200
Today’s High 1.14
Today’s Low 1.09
52 Week High 2.17
52 Week Low 0.74
Shares Outstanding (mil) 147.00
Market Capitalization (mil) 299.88
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
9
FY16
14
FY15
19
EPS (USD)
FY17
-0.127
FY16
-0.259
FY15
-0.191
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
18.57
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
-109.40
14.43
Return on Equity (TTM)
vs sector
-411.96
16.13

EXECUTIVE LEADERSHIP

Felix Theeuwes
Chairman, Chief Scientific Officer, Since 1998
Salary: $277,452.00
Bonus: --
James Brown
President, Chief Executive Officer and Director, Since 1998
Salary: $470,385.00
Bonus: --
Matthew Hogan
Chief Financial Officer, Since 2006
Salary: $322,093.00
Bonus: --
Judy Joice
Senior Vice President - Operations and Corporate Quality Assurance, Since 2014
Salary: $275,782.00
Bonus: --
Myriam Theeuwes
Senior Vice President - Clinical Development, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10260 Bubb Rd
CUPERTINO   CA   95014-4166

Phone: +1408.7771417

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.

SPONSORED STORIES